Piper Sandler Initiates Coverage On Cerevel Therapeutics Hldg With Overweight Rating, Announces Price Target of $33
Piper Sandler Initiates Coverage On Cerevel Therapeutics Hldg With Overweight Rating, Announces Price Target of $33
派珀·桑德勒以增持評級開始對Cerevel Therapeutics Hldg進行保險,宣佈目標股價爲33美元
Piper Sandler analyst David Amsellem initiates coverage on Cerevel Therapeutics Hldg (NASDAQ:CERE) with a Overweight rating and announces Price Target of $33.
Piper Sandler分析師David·阿姆塞萊姆以增持評級啟動對Cerevel Treateutics Hldg(納斯達克:CERE)的報道,並宣佈目標價為33美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。